Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

PHASE3CompletedINTERVENTIONAL

Enrollment

393

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

September 25, 2019

Study Completion Date

March 5, 2020

Conditions

Breast CancerNeutropenia

Interventions

DRUG

F-627

single dose pre-filled syringe

DRUG

Neulasta

single dose pre-filled syringe

Trial Locations (1)

University of California Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center (JCCC), Los Angeles